Novo Nordisk and Eli Lilly, which provide some funding to The Obesity Society and the Endocrine Society and partner with AACE, would not say whether they were engaging with medical associations on the creation of new guidelines. 2023 March 30, Patrick Wingrove, “Focus: As weight-loss drugs hit the U.S. market, doctors debate how to use them”, in Reuters: